Evidence map›Paper›PMID 31772650›Full record

ArticleJournal of Cancer2019

Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial.

Seung Tae Kim, Sung Yong Oh, Jeeyun Lee, Jung Hun Kang, Hyun Woo Lee, Myung Ah Lee, Byeong Seok Sohn, Ji Hyong Hong, Young Suk Park, Joon Oh Park and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. A review of systemic therapy in biliary tract carcinoma.Journal of gastrointestinal oncology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Seung Tae KimDepartment of Medicine, Sungkyunkwan University School of Medicine, Samsung Medical Centre, Seoul, South Korea.
Sung Yong OhDepartment of Medicine, Dong-A University School of Medicine, Busan, South Korea.
Jeeyun LeeDepartment of Medicine, Sungkyunkwan University School of Medicine, Samsung Medical Centre, Seoul, South Korea.
Jung Hun KangDepartment of Medicine, Gyeongsang National University Hospital, Jinju, South Korea.
Hyun Woo LeeDepartment of Medicine, Ajou University School of Medicine, Suwon, South Korea.
Myung Ah LeeDepartment of Medicine, Seoul St Mary's Hospital, Catholic University, Seoul, South Korea.
Byeong Seok SohnDepartment of Medicine, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, South Korea.
Ji Hyong HongDepartment of Medicine, Incheon St Mary's Hospital, Catholic University, Incheon, South Korea.
Young Suk ParkDepartment of Medicine, Sungkyunkwan University School of Medicine, Samsung Medical Centre, Seoul, South Korea.
Joon Oh ParkDepartment of Medicine, Sungkyunkwan University School of Medicine, Samsung Medical Centre, Seoul, South Korea.
Ho Yeong LimDepartment of Medicine, Sungkyunkwan University School of Medicine, Samsung Medical Centre, Seoul, South Korea.
Ajou University · KRGyeongsang National University Hospital · KRInje University Sanggye Paik Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

biliary tract cancercapecitabineoxaliplatin

Identifiers

PMID31772650
PMCPMC6856733
OpenAlexW2982416431

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.